Pharmacophore generation and atom-based 3D-QSAR of -iso-propyl pyrrole-based derivatives as HMG-CoA reductase inhibitors by unknown
Teli and K Organic and Medicinal Chemistry Letters 2012, 2:25
http://www.orgmedchemlett.com/content/2/1/25ORIGINAL ARTICLE Open AccessPharmacophore generation and atom-based
3D-QSAR of N-iso-propyl pyrrole-based
derivatives as HMG-CoA reductase inhibitors
Mahesh Kumar Teli and Rajanikant G K*Abstract
Background: Coronary heart disease continues to be the leading cause of mortality and a significant cause of morbidity
and account for nearly 30% of all deaths each year worldwide. High levels of cholesterol are an important risk factor for
coronary heart disease. The blockage of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity by small
molecule inhibitors has been shown to inhibit hypercholesterolemia. Herein, we describe the development of effective
and robust pharmacophore model and the structure–activity relationship studies of 43N-iso-propyl pyrrole-based
derivatives previously reported for HMG-CoA reductase inhibition.
Results: A 5-point pharmacophore model was developed and the generated pharmacophore model was used to derive
a predictive atom-based 3D quantitative structure–activity relationship analysis (3D-QSAR) model for the studied dataset.
The obtained 3D-QSAR model has an excellent correlation coefficient value (r2 = 0.96) along with good statistical
significance as shown by high Fisher ratio (F=143.2). The model also exhibited good predictive power confirmed by the
high value of cross validated correlation coefficient (q2 = 0.672). Further, pharmacophoric model was employed for virtual
screening to identify four potential HMG-CoA reductase inhibitors.
Conclusions: The QSAR model suggests that electron-withdrawing character is crucial for the HMG-CoA reductase
inhibitory activity. In addition to the electron-withdrawing character, hydrogen bond--donating groups, hydrophobic
and negative ionic groups positively contribute to the HMG-CoA reductase inhibition. These findings provide a set of
guidelines for designing compounds with better HMG-CoA reductase inhibitory potential.
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High levels of cholesterol are linked to atherosclerosis,
which is the accumulation of cholesterol-rich fatty depos-
its in arteries. This can cause arteries to narrow or become
blocked, slowing or stopping the flow of blood to vital
organs, especially the heart, brain and kidney [1-5]. When
atherosclerosis blocks arteries that supply blood to the
brain, it can cause an ischemic stroke. Atherosclerotic
heart disease is the leading cause of death, accounting for
one-third of all deaths and atherosclerotic interference
with blood supply to the brain (ischemic stroke) is the
third most common cause of death after cancer [6-9]. The
biosynthetic pathway for cholesterol involves more than* Correspondence: rajanikant@nitc.ac.in
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in any medium, provided the original work is p25 different enzymes and the major rate-limiting step in
this pathway is regulated by the 3-hydroxy- 3-
methylglutaryl Coenzyme A (HMG-CoA) reductase. In-
hibition of HMG-CoA reductase leads to a decrease in
intrahepatic cholesterol concentration [10-14].
In recent years, several successful strategies for the in-
hibition of cholesterol biosynthesis have effectively been
demonstrated in preclinical and clinical settings. For
examples, ezetimibe and statins have been approved for
the treatment of hypercholesterolemia [15-17]. Up to
now, there are still a lot of researches focusing on the
development of novel inhibitors of HMG-CoA reductase
[16,17]. Recently, a novel series of HMG-CoA reductase
inhibitors, which can selectively inhibit HMG-CoA re-
ductase with high inhibitory activities, has been reported
by Pfefferkorn et al. [18].is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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inhibitors in mind and our continuing interest in the de-
velopment of HMG-CoA reductase inhibitors, a 3D
quantitative structure–activity relationship analysis (3D-
QSAR) was proposed on the series of N-iso-propyl
pyrrole-based derivatives reported for HMG-CoA reduc-
tase inhibitory activity [18]. The compounds reported
were used for the purpose of 3D-QSAR modeling since
they have a common scaffold and the biological assays
have been carried out in the same lab.
3D-QSAR is widely used in the lead optimization stage
and provides valuable insights about ligand–protein inter-
actions [19,20]. In order to establish relationship between
the spatial 3D pharmacophoric features and HMG-CoA
reductase inhibitors activity of a group of N-iso-propyl
pyrrole-based derivatives, a 3D-QSAR analysis was carried
out on the combined dataset employing PHASE module
of Schrodinger molecular modeling software [21].
In this study, we have developed a quantitative pharma-
cophore model based on HMG-CoA reductase inhibitors
collected from the same laboratory [18]. The best quanti-
tative model was used as a 3D search query for screening
the ZINC database to identify new inhibitors of HMG-
CoA reductase. Once identified, the candidate compounds




A set of 43N-iso-propyl pyrrole-based derivatives with
well-defined HMG-CoA reductase inhibitory activity
was used for the QSAR analysis [18]. In vitro inhibitory
concentrations (IC50) of the molecules against HMG-
CoA reductase were converted into corresponding pIC50
[−log(IC50)] and were used as dependent variables in the
QSAR calculations (Additional file 1).
Molecular modeling
PHASE 3.0 module of Schrodinger molecular modeling
software was used to generate pharmacophore models
[21]. In QSAR studies, appropriate conformation (lowest
energy) of the compound is required for accurate calcu-
lation of 3D descriptors. All the 43 compounds were
sketched by Maestro. Further, geometry optimization
was carried out using the semi-empirical OPLS_2005
force field. All the molecules were divided into a training
set and test set to maintain the structure and activity di-
versity in both the sets for QSAR model and pharmaco-
phore generation and validation.
PHASE incorporates a structure cleaning step utilizing
LigPrep, which attaches hydrogens, converts 2D structures
to 3D, generates stereoisomers and neutralizes charged
structures or determines the most probable ionization state
at a user-defined pH. It also allows for the importation of3D structures prepared outside its own workflow. Because
one does not generally know the structure that a given mol-
ecule will adopt if and when it binds to a target protein, it is
customary to represent each molecule as a series of 3D
structures that sample the thermally accessible conform-
ational states. For the purposes of pharmacophore model
development, PHASE provides two built-in approaches,
both of which employ the MacroModel conformational
search engine. Since most of the studied ligands were flex-
ible, all possible conformations for a ligand were generated
to consider a range of conformations in order to increase
the chances of finding the most active conformer close to
the bound structure. Accordingly, the prepared ligands
were subjected to conformational analysis using Monte-
Carlo Multiple Minimum method implemented in the
Schrodinger software.
The ligands were assigned as active and inactive by giv-
ing an appropriate activity threshold value. The threshold
value was 6 for active legend and 5 for inactive ligand.
The activity threshold value was selected on the basis of
dataset activity distribution (4.427–6.699) and the active
ligands were chosen to derive a set of suitable pharmaco-
phores. The so-prepared ligands were used for generating
common pharmacophore and QSAR model building.
Creation of pharmacophore sites
The chemical features of all ligands were defined by six
pharmacophorics features: H-bond acceptor (A), H-
bond donor (D), hydrophobic group (H), negatively
charged group (N), positively charged group (P), and
aromatic ring (R). An active analog approach was used
to identify common pharmacophore hypotheses (CPHs),
in which common pharmacophores were culled from
the conformations of the set of active ligands using a
tree-based partitioning technique that groups together
similar pharmacophores according to their intersite dis-
tances [21].
Scoring pharmacophores with respect to active and
inactive ligands
The resulting pharmacophores were then scored and
ranked. The scoring was done to identify the best candi-
date hypothesis, which provided an overall ranking of all
the hypotheses. The scoring algorithm included the con-
tributions from the alignment of site points and vectors,
volume overlap, selectivity, number of ligands matched,
relative conformational energy, and activity [22].
Perceiving common pharmacophores
After the careful analysis of the scores and alignment of
the active ligands to the generated hypothesis, a best
pharmacophore hypothesis AANRR (Figure 1a) was
selected for further studies (Table 1). The selected 3D
pharmacophore hypothesis (Figure 1b) encompassed the
Figure 1 Common pharmacophore generation and validation: (a) Common pharmacophore aligned with most active ligand [two aromatic
rings (dark yellow circle)], two acceptor [pink sphere with two arrows], and one negative ionic [pink sphere]; (b) common pharmacophoric sites
of active ligand with distance. All distances are in Å unit; (c) alignment of all active ligands to the pharmacophore; and (d) alignment of all
ligands (active and inactive) to the pharmacophore.
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(pink sphere with two arrows), one negatively charged
group (N) (pink sphere), two aromatic rings (R) (grey
circle). The 2D representation (Figure 1a) of the
pharmacophore AANRR shows the two hydroxyl groups
(pink sphere with two arrows) hydrogen bond acceptor
(A), carboxyl group (pink sphere) negatively charged
group (N), pyrrole and benzene side chain rings viz. R11
and R12 are as the key pharmacophoric elements
present in the selected pharmacophore.
Building 3D-QSAR models
QSAR modeling was carried out using the selected hy-
pothesis by dividing the dataset in to training set (70%)
and test set (30%) in a random manner. PHASE presents
two options for alignment of 3D structure of molecules:
the pharmacophore based alignment and the atom-basedalignment [21,23]. In this study, we have used an atom-
based QSAR model, which is more useful in explaining
the structure–activity relationship. In atom-based QSAR,
a molecule is treated as a set of overlapping van der Waal’s
spheres. Each atom (and hence each sphere) is placed into
one of six categories according to a simple set of rules:
hydrogens attached to polar atoms are classified as hydro-
gen bond donors (D); carbons, halogens, and C–H hydro-
gens are classified as hydrophobic/non-polar (H); atoms
with an explicit negative ionic charge are classified as
negative ionic (N); atoms with an explicit positive ionic
charge are classified as positive ionic (P); non-ionic nitro-
gen and oxygen are classified as electron-withdrawing
(W); and all other types of atoms are classified as miscel-
laneous (X).
For the purpose of QSAR development, van der Waal’s
models of the aligned training set molecules were placed
Table 1 Score of different parameters of the AANRR hypothesis
ID Survival Survival-inactive Site Vector Volume Selectivity Matches Energy Activity Inactive
AANRR 3.603 1.593 0.9 0.967 0.732 2.077 12 4.741 6.097 2.011
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or more ‘bits’ to account for different types of atoms in
the training set that occupy the cube. This representa-
tion gives rise to binary-valued occupation patterns that
can be used as independent variables to create partial
least-squares (PLS) QSAR models. Atom-based QSAR
models were generated for the selected hypothesis using
the 31-member training set using a grid spacing of
1.0 Å. The best QSAR model was validated by predicting
activities of the 12 test set compounds. A four-
component (PLS factor) model with good statistics was
obtained for the dataset whereas the maximum number
of PLS factors in each model can be 1/5 of the total
number of training set molecules. Further increase in
the number of PLS factors did not improve the model
statistics or predictive ability [19].
Protein preparation
The HMG-CoA reductase (PDB ID: 2R4F) was prepared
using the Protein Preparation Wizard of the Schrödinger
suite. H-atoms were added to the protein, including the
protons necessary to define the correct ionization and
tautomeric states of amino acid residues such as Asp,
Ser, Glu, Arg, and His. The missing side chains of resi-
dues were corrected using Build interface incorporated
in Maestro. For each structure, minimization was carried
out with the Impact Refinement module, using the
OPLS-2005 force field to alleviate steric clashes that
may exist in the structures. The minimization was termi-
nated when the energy converged or the Root Mean
Square Deviation (RMSD) reached a maximum cutoff of
0.30 Å [24]. After protein preparation, receptor grid was
set up, which was generated by employing the Receptor
Grid Generation panel. Since this protein was associated
with ligand, the ligand was selected to define the
position and size of the active site.
Virtual screening
AANRR hypothesis was used to search a 3D database
for structures that match the pharmacophoric features
of the model. Virtual screening was carried out using
ZincPharmer that uses the pharmacophore to efficiently
search the ZINC database of fixed conformers for
pharmacophore matches [25,26]. To accomplish the best
3D similarity search, we used constraints that included
maximum of 0.7 RMSD, obeying 10 rotatable bond cut-
off and molecular weight range of 180–500 Dalton. A
molecule which fits well with the pharmacophoric fea-
tures of the AANRR hypothesis was retrieved as a hit.Docking methodology
All the hits with good RMSD value were enlisted and
were incorporated to Maestro. Hits were subjected to
hydrogen additions, removal of salt, ionization and gen-
eration of low-energy ring conformations using LigPrep.
The chiralities of the original compounds were pre-
served. Finally, the low-energy 3D structures of all com-
pounds were produced. The virtual screening workflow
(VSW) in Maestro was used to dock and to score the
lead-like compounds. In the first step, Glide was run in
high-throughput virtual screen mode. 10% of the top-
scoring ligands were kept to go onto the next, Glide Sin-
gle Precision (SP), stage. The top-scoring 10% leads from
GlideSP were retained and docked with Glide XP. All
the Glide protocols were run using default parameters.
An extensive search was carried out for generating all
possible conformations. Minimization cycle for conju-
gate gradient and steepest descent minimizations were
used with default value of 0.05Å for initial step size and
1.0Å for maximum step size. In convergence criteria for
the minimization, both the energy change criteria and
gradient criteria were used with default values of 10-7
and 0.001 kcal/mol, respectively. Then, all conformations
were considered for docking. During the docking
process, the Glide-score was used to select the best con-
formation for each ligand.
Results and discussion
The aim of this study was to elucidate the 3D structural
features of N-iso-propyl pyrrole-based derivatives (Table 2)
crucial for binding, by generating 3D pharmacophore and
to quantify the structural features of HMG-CoA reductase
inhibitors essential for biological activity by generating
atom-based 3D QSAR model. For the pharmacophore
modeling and QSAR studies, we have used Phase module
of Schrodinger suite. This hypothesis generated by Phase
will also convey the relative binding of the ligands inside
the active site of the receptor. Hence, we have used
conformation suggested by the hypothesis for generating
3D-QSAR model to identify overall aspects of molecular
structure that govern the activity.
For the generation of pharmacophore model, we have
considered 12 compounds having activity > 6 against
HMG-CoA reductase as active as they contain important
structural features crucial for binding to the receptors
binding site. We used four minimum sites and five max-
imum sites to have optimum combination of sites or fea-
tures common to the most active compounds. One
hundred and two common pharmacophore models were
Table 2 PLS statistical parameters of the selected 3D-QSAR model
ID PLS factors SD R2 F P RMSE Q2 Pearson-R
AANRR 1 0.4323 0.5171 31 5.181e-006 0.4018 0.3971 0.6346
2 0.3191 0.7459 41.1 4.687e-009 0.4157 0.3549 0.676
3 0.2369 0.865 57.7 7.249e-012 0.3565 0.5255 0.7782
4 0.1369 0.9566 143.2 2.609e-017 0.2965 0.6719 0.8371
SD, standard deviation of the regression; R, squared value of R2 for the regression; F, variance ratio. Large values of F indicate a more statistically significant
regression, P, significance level of variance ratio. Smaller values indicate a greater degree of confidence; RMSE,root-mean-square error, Q, squared value of Q2 for
the predicted activities, Pearson-R, Pearson R value for the correlation between the predicted and observed activity for the test set.
Figure 2 Fitness graph between observed activity versus
phase-predicted activity for training and test set compounds.
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all models were considered for further QSAR generation;
the results were illustrated in (Additional file 2). Among
these pharmacophores, the models which are showing the
superior alignment with active compounds were identified
by mapping to them and calculating the survival score.
The survival scoring function identifies the best candidate
hypothesis from the generated models and provides an
overall ranking of all the hypotheses. The scoring algo-
rithm includes contributions from the alignment of site
points and vectors, volume overlap, selectivity, number of
ligands matched, relative conformational energy, and ac-
tivity. However, these pharmacophore models should also
discriminate between the active (most active) and inactive
(less active) molecules (Table 1). It is true that the hypoth-
esis is incomplete if it lacks either a critical site that
explains the binding or information on what prevents in-
active ligands from binding. To identify the pharmaco-
phore models with more active and less inactive features
among these models, they were mapped to inactive com-
pounds and scored. If inactive ligands score well, the hy-
pothesis could be invalid because it does not discriminate
between active and inactive ligands. Therefore, adjusted
survival score was calculated by subtracting the inactive
score from survival score of these pharmacophores
(Additional file 2). Finally the models with maximum
adjusted survival score and lowest relative conformational
energy ware selected for generating pharmacophore
(atom)-based alignment of HMG-CoA reductase inhibi-
tors and model AANRR has been chosen because it pro-
duced good predictive power above other models. The
special arrangement of features along with their distance
present in five-featured pharmacophore, AANRR, was
shown in Figure 1a. As depicted in the figure, among the
two ring aromatic features, one feature is mapped to the
pyrrole ring of all 12 active inhibitors and another on ben-
zene side chain attached to pyrrole ring. The both hydro-
gen bond acceptor and negative ionic features are mapped
to (the hydroxyl groups and carboxyl group) on N-iso-
propyl side chain substituted on pyrrole ring.
For generating an atom-based 3D QSAR hypothesis,
we have used a dataset of 31 (training set) compounds
having inhibitory activity against HMG-CoA reductase.
The model was validated using 12 (test set) compounds,which cover wide range of HMG-CoA reductase inhibi-
tory activity. The alignment generated by the best
pharmacophore model AANRR was used for QSAR
model generation (Figure 1). Figure 1c presents good
alignment of the active ligands and scattered alignment
of inactive ligands to the developed pharmacophore
model. Alignments of actives and of all inhibitors (active
and inactive) are shown in Figure 1c,d, respectively.
From Figure 1 we can easily identify that active ligand is
having good alignment than inactive one. A four-PLS
factor model with good statistics and predictive ability
was generated for the dataset (Table 2). The number of
PLS factor included in model development is four as in-
cremental increase in the statistical significance and pre-
dictivity was observed for each incremental increase in
the incorporated PLS factors up to four. The model ex-
press 95% variance exhibited by N-iso-propyl pyrrole-
based derivatives, which is near to one and signifying a
close agreement of fitting points on the regression line
for the observed and PHASE-predicted activity that can
be visualized from Figure 2 and is summarized in
Table 3.
Table 3 Fitness and predicted activity data for test and training set of compounds
Serial numbers Ligand name QSAR set Activity PLS factors Predicted activity Pharm set Fitness
1 228583 Training 4.427 4 4.49 Inactive 1.61
2 228954 Training 4.932 4 4.85 Inactive 1.6
3 228955 Training 6.523 4 6.67 Active 2.33
4 249273 Training 5.469 4 5.53 2.85
5 249724 Training 6.097 4 6.31 Active 2.85
6 249884 Training 4.921 4 5.2 Inactive 2.85
7 250088 Training 5.18 4 5.18 1.58
8 250090 Training 4.699 4 4.57 Inactive 1.57
9 250317 Training 6.523 4 6.5 Active 2.32
10 250500 Training 4.824 4 4.88 Inactive 2.36
11 250707 Training 5.42 4 5.41 2.79
12 250749 Training 6.155 4 6.19 Active 2.79
13 250953 Training 5.538 4 5.5 2.29
14 251499 Training 5.921 4 5.76 2.67
15 389216 Training 5.538 4 5.47 2.53
16 389217 Training 4.785 4 4.78 Inactive 2.2
17 389442 Training 5.523 4 5.57 2.55
18 391002 Training 5.523 4 5.43 2.62
19 394937 Training 5.745 4 5.78 2.8
20 398239 Training 5.824 4 5.76 2.87
21 398551 Training 6.222 4 6.3 Active 2.37
22 399313 Training 6.097 4 6.11 Active 2.98
23 399315 Training 5.745 4 5.59 2.19
24 399360 Training 4.907 4 5 Inactive 1.51
25 399771 Training 5.056 4 5.2 2.86
26 400560 Training 5.585 4 5.6 2.89
27 400874 Training 6.699 4 6.46 Active 2.89
28 400973 Training 6.398 4 6.06 Active 2.75
29 401293 Training 5.658 4 5.73 1.5
30 403127 Training 5.854 4 5.8 2.3
31 437774 Training 6.523 4 6.65 Active 2.3
32 228528 Test 5.721 4 5.62 2.53
33 228667 Test 5.018 4 5.22 1.64
34 249906 Test 5.921 4 6.06 2.9
35 387514 Test 5.456 4 5.58 2.4
36 389002 Test 5.745 4 5.95 2.34
37 389441 Test 4.857 4 4.78 Inactive 2.19
38 389443 Test 5.328 4 4.68 1.62
39 398240 Test 6.097 4 5.85 Active 3
40 399773 Test 6.523 4 6.06 Active 2.29
41 400747 Test 6.155 4 5.76 Active 2.78
42 438662 Test 4.777 4 4.9 Inactive 2.22
43 438694 Test 5.523 4 5.74 2.39
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N-iso-propyl pyrrole-based derivatives to understand the
effect of spatial arrangement of structural features on
their HMG-CoA reductase inhibition. The large value of
F (143.2) indicates a statistically significant regression
model, which is also supported by the small value of the
variance ratio (P), an indication of a high degree of con-
fidence. Further, small values of standard deviation
(0.137) of the regression and RMSE (RMSE= 0.296)
makes an obvious implication that the data used for
model generation are best for the QSAR analysis. Valid-
ity of the model can be expressed by cross-validated cor-
relation coefficient (q2 = 0.672) that was obtained by
leave one out or leave N out method. The q2 is more re-
liable and robust statistical parameter than r2 because it
is obtained by external validation method by dividing
the dataset into training and test set.
The atoms visualize 3D characteristics of the ligands
(atoms or pharmacophores) as that contribute positively
or negatively to activity. The QSAR model displays 3D
characteristics (Figure 3) as cubes that represent the
model and color according to the sign of their coefficient
values, which by default is blue for positive coefficients
and red for negative coefficients. Positive coefficients in-
dicate an increase in activity, negative coefficients a de-
crease. The visualization of the coefficients is useful to
identify characteristics of ligand structures that tend to
increase or to decrease the activity. This might give a
clue to what functional groups are desirable or undesir-
able at certain positions in a molecule. The blue cubes
in 3D plots of the 3D pharmacophore regions refer to
ligand regions in which the specific feature is important
for better activity, whereas the red cubes demonstrates
that particular structural feature or functional group,
which is not essential for the activity or likely the reason
for decreased binding potency.
Visual analysis of Figure 3a demonstrates that the
presence of the blue cubes at the A2, A3, N10
(N-iso-propyl side chain), cyano group, and amide
group (carbamoyl side chain) attached to pyrrole ring is
pointing out the positive potential of electron withdraw-
ing characteristic of the molecules and is requisite for
the activity at this particular place. It can be suggested
that addition of appropriate electron withdrawing
groups at the A2, A3, cyano, and amide (carbamoyl side
chain) sites will append the HMG-CoA reductase inhib-
ition, whereas the addition of electron-withdrawing
groups near carboxy group attached to pyrrole ring
position will contribute to decreased receptor binding,
which in turn will result in lower potency of com-
pounds because red color cubes are for negative effect
of electron-withdrawing group to that particular place.
Figure 3b illustrates that H-bond donor characteristic is
necessary at A2 and A3 (N-iso-propyl side chain)present on the pyrrole ring. The red cubes at the ben-
zene ring attached to the amide side chain of pyrrole
ring demonstrate a negative potential of H-bond donor
at that position on the compounds. Figure 3c demon-
strates the effect of hydrophobic groups on HMG-CoA
reductase inhibition. It can be deduced from the figure
that hydrophobic groups are well tolerated near cyano
benzene ring on carbamoyl side chain (blue cubes),
while the substitution of hydrophobic groups in be-
tween amide (carbamoyl side chain) and cyano benzene
ring site are unacceptable (red cubes) or may hinder
the binding of the molecules to the receptor active site and
will result in decreased HMG-CoA reductase inhibition.
Further, Figure 3d showed combined effect of all the fea-
tures. The presence of hydroxyl groups (N-iso-propyl side
chain), cyano group, and amide group (carbamoyl side
chain) will have the positive effect (blue cubes).
Virtual screening
One efficient approach to drug discovery is the virtual
screening of the molecular libraries. Pharmacophore-
based database searching is considered as a type of
ligand-based virtual screening, which can efficiently be
used to find novel and potential leads for further devel-
opment. A potent pharmacophore model possesses the
chemical functionalities responsible for bioactivities of po-
tential drugs; therefore, it can be used to perform a data-
base search by serving as a 3D query. The pharmacophore
AANRR was used as a 3D structural query for retrieving
potent molecules from the ZINC chemical database
through ZincPharmer. To avoid possible incorrect predic-
tions, the molecular weight cutoff of 180–500 Dalton
range, RMSD of 0.7, and cutoff limit of 10 rotatable bonds
filters were applied. Altogether, 3D structural query
retrieved 17,283 compounds from the ZINC database.
Drug likeness analysis
The ZINC database was evaluated for drug-likeness of
the lead molecules by assessing their physicochemical
properties and by applying Lipinski’s rule of five. Their
molecular weights were <500 Daltons with <5H-bond
donors, <10H-bond acceptors and a log p of <5; these
properties were well within the acceptable range of the
Lipinski rule for drug-like molecules.
These compounds were further evaluated for their
drug-like behavior through the analysis of pharmacoki-
netic parameters required for absorption, distribution,
metabolism, and excretion (ADME). For the four lead
compounds, the partition coefficient (QPlogPo/w) and
water solubility (QPlogS), critical for estimation of ab-
sorption and distribution of drugs within the body, ran-
ged between −2 to 6.5 and −6 to −0.5, respectively.
Further, the blood brain barrier permeability, which is
prerequisite for the entry of drugs to the brain, was
Figure 3 QSAR visualization of various substituents effect: (a) electron withdrawing feature; (b) hydrogen-bond donor; (c) hydrophobic
features; and (d) combined effect (blue cubes showing positive potential while red cubes showing negative potential of particular substitution).
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the percentage human oral absorption of all four com-
pounds ranged from 30 to 79%. All these pharmacoki-
netic parameters were within the acceptable range
defined for human use, thereby indicating their potential
as drug-like molecules (Table 4).
Molecular docking
Docking was carried out to increase the power of the
pharmacophore-based screening to discriminate between
the active and inactive ligands (that could adopt poses to
accomplish the pharmacophore features). The docking
was especially useful during the second step of the VS
workflow for the identification of molecules having at
least one conformer that irrespective of its initial spatialorientation, can fit into the pharmacophore (because
docking can be used to exclude those inactive molecules
from the VS having at least one conformer, which
matches the sites in the pharmacophore but is sterically
hindered by other residues in the active site).
To further refine the retrieved candidates, the 17,283
candidates were docked (VSW) into the active site of
HMG-CoA reductase and screened through developed
QSAR model in order to predict the activities. The
binding modes for these compounds identified by dock-
ing were ranked according to the information obtained
by different scoring constraints. Based on the knowledge
of existing HMG-CoA reductase inhibitors, ADME
properties, docking score, and the active site require-
ments, we selected four compounds from highest
Table 4 ADME properties of selected hits with the docking score
ZINC ID logPo/wa logSb logHERGc logBBd % Oral absorptione Predicted activity Docking score
14010678 3.61 −5.58 −3.61 −1.97 57.81 5.7 −9.22
35655503 2.05 −4.10 −2.87 −1.04 70.66 5.52 −9.34
26508465 −0.97 −2.25 −3.06 −2.22 32.50 5.98 −9.16
02554357 3.45 −6.05 −3.93 −0.92 79.57 5.23 −8.95
aPredicted octanol/water partition co-efficient log p (acceptable range: −2.0 to 6.5).
bPredicted aqueous solubility; S in mol/L (acceptable range: −6.5 to 0.5).
cPredicted IC50 value for blockage of HERG K+ channels (acceptable range: below −6.0).
dPredicted blood brain barrier permeability(acceptable range: −3 to 1.2).
ePercentage of human oral absorption (.25% is poor and .80% is high).
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exhibit highest binding affinities and the predicted activ-
ity (Table 4). The diversity of the candidates demon-
strated that the pharmacophore model was able to
retrieve candidates with similar features to the existing
HMG-CoA reductase inhibitors as well as novel scaf-
folds (Figure 4).
Conclusion
A ligand-based pharmacophore model was generated for
the series of N-iso-propyl pyrrole-based derivatives with
HMG-CoA reductase inhibitory activity to reveal the struc-
tural features responsible for biological activity. With the
help of pharmacophore-based alignment of HMG-CoA re-
ductase inhibitors, a meaningful 3D-QSAR was derived toFigure 4 The chemical structures of final hits represented in 2D withidentify and how three-dimensional arrangements of vari-
ous substituents will affect the HMG-CoA reductase inhib-
ition. The selected model as shown by the correlation
statistics and predictive statistics is very much significant to
draw unambiguous inferences. Further, the generated 3D-
QSAR model also explains how and at what extent electron
withdrawing, hydrophobic and H-Donor moieties in the
molecular structure influences HMG-CoA reductase inhib-
ition showed by the title compounds. The model shows
that HMG-CoA reductase inhibition can be increased, if
the electron-withdrawing character near N-iso-propyl side
chains is supplemented by appropriate functional groups
and by the incorporation of H-donor, hydrophobic, and
positive ionic groups at specific positions in the molecules.
Finally, four potential hits with good fitness value anddocking scores.
Teli and K Organic and Medicinal Chemistry Letters 2012, 2:25 Page 10 of 10
http://www.orgmedchemlett.com/content/2/1/25predicted activity were identified by virtual screening and
docking, whose activity can be further improved with the
help of this QSAR model. This study provides a set of
guidelines which will greatly help in designing the newer
and more potent HMG-CoA reductase inhibitors of the N-
iso-propyl pyrrole-based scaffold.
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